NL-OMON32699已完成2 期
An Open label Follow-On Study to Assess the Ongoing Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis. - MAESTRO-02 (MBP8298-SP-02)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subjects participating in this study must have completed treatment and all required evaluations in the previous MBP8298-01 study *A Double Blind Placebo Controlled Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis*,
- •2. Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial in accordance with regulatory requirements,
- •3. In the Investigator*s opinion, subjects must be reliable, compliant and agree to cooperate with all trial evaluations.
排除标准
- •1. Use of any concomitant disease modifying therapy for Multiple Sclerosis e.g. ß-interferon, glatiramer acetate or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating (e.g. IVIG) or immunosuppressive drugs including recombinant or non-recombinant cytokines.
- •2. Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements.
- •3. Any other condition that, in the Investigator*s opinion, makes the subject unsuitable for participation in the study.
- •4. Females who are breast feeding, pregnant or not using a medically approved method of contraception regularly.
研究者
相似试验
已完成
不适用
An open-label follow-on study to assess the ongoing safety of MBP8298 in subjects with secondary progressive multiple sclerosisNervous System DiseasesSecondary Progressive Multiple SclerosisMultiple SclerosisISRCTN31894936BioMS Medical (Canada)600
进行中（未招募）
1 期
A Long-term Follow-up Study of Sotatercept for PAH TreatmentPulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-005061-13-NLAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA700
招募中
3 期
A Long-term Follow-up Study of Sotatercept for PAH Treatment2023-509138-21-00Acceleron Pharma Inc.407
进行中（未招募）
1 期
A Long-term Follow-up Study of Sotatercept for PAH TreatmentPulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-005061-13-ATAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA700
进行中（未招募）
1 期
A Long-term Follow-up Study of Sotatercept for PAH TreatmentPulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-005061-13-SEAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA700